Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410x.1995.tb07251.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does Pelvic Congestion Cause Bladder Symptoms-Potential New Indication to Treat Pelvic Congestion.
J Med Imaging Radiat Oncol
January 2025
Sydney Fibroid Clinic, Sydney, New South Wales, Australia.
Background: Pelvic Congestion Syndrome (PCS) is a condition characterised by chronic pelvic pain resulting from the dilation and reflux of veins within the pelvis. While pelvic pain is the primary symptom of PCS, other associated symptoms may vary among individuals. Bladder symptoms have been commonly observed in PCS, including increased urination frequency, urinary urgency, nocturia and rarely haematuria.
View Article and Find Full Text PDFPessary Placement for Voiding Dysfunction Due to Prolapse Among Neurologically Intact Women.
Urogynecology (Phila)
January 2025
Division of Female Pelvic Medicine and Reconstructive Surgery, Northwestern Medicine, Chicago, IL.
Importance: Literature surrounding conservative management of voiding dysfunction (VD) due to pelvic organ prolapse (POP) is limited.
Objective: The objective of this study was to evaluate the effect of pessaries on VD in women with symptomatic POP.
Study Design: This was a retrospective case series of adult women who underwent a pessary fitting for POP and VD between January 2010 to December 2022 at 2 tertiary care centers.
Prostatic aggressive angiomyxoma (AAM) with initial presentation of urinary obstruction: a rare case report and literature review.
Transl Androl Urol
December 2024
Department of Urology, Peking University People's Hospital, Beijing, China.
Background: Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumor known for its aggressive behavior and high recurrence rates, with male cases of AAM being less frequently reported. This study presents a rare case of primary prostatic AAM characterized by a prostatic urethral mass obstructing the bladder outlet, resulting in acute renal dysfunction.
Case Description: The 51-year-old male patient presented with lumbar pain, nausea, frequent urination, urgency, and incomplete urination.
Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma and muscle-invasive bladder cancer. This study evaluates the safety and efficacy of tislelizumab combined with low-dose nab-paclitaxel in extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC).
Patients And Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients with visually incomplete resection and/or high-volume high-grade T1 tumors (with or without carcinoma in situ), who were ineligible for or declined radical cystectomy.
NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA.
bioRxiv
December 2024
The Russell H. Morgan Department of Radiology and Radiological Science.
The optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study demonstrates the utility of Nectin-4-targeted positron emission tomography (PET) imaging using [Ga]AJ647 as a non-invasive tool for real-time assessment of target engagement in enfortumab vedotin (EV) therapy for urothelial carcinoma (UC). By leveraging the specificity of [Ga]AJ647 for Nectin-4, we quantified dynamic changes in target engagement across preclinical models and established its correlation with therapeutic outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!